Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. Tu HY, et al. Among authors: srinivasa bj. Target Oncol. 2022 Jan;17(1):1-13. doi: 10.1007/s11523-021-00859-6. Epub 2022 Jan 12. Target Oncol. 2022. PMID: 35020119 Free PMC article. Clinical Trial.
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL. Passaro A, et al. Among authors: srinivasa bj. Front Oncol. 2021 Jul 9;11:709877. doi: 10.3389/fonc.2021.709877. eCollection 2021. Front Oncol. 2021. PMID: 34307179 Free PMC article.
Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience.
Srinivasa BJ, Lalkota BP, Badarke G, Hazarika D, Mohammad N, Sapkota S, Khanderia M, Tousif D, Rao R, Ram A, Patil S, Naik R. Srinivasa BJ, et al. Clin Med Insights Oncol. 2018 Jun 28;12:1179554918782475. doi: 10.1177/1179554918782475. eCollection 2018. Clin Med Insights Oncol. 2018. PMID: 30046259 Free PMC article.
Recurrent squamous cell carcinoma of the skin treated with immunotherapy.
Srinivasa BJ, Sridhar PS, Lalkota BP, Tsikai N, Niyati PS, Shah M, Anuradha S, Roopesh R, Ramaswamy V, Naik R, Ajaikumar BS. Srinivasa BJ, et al. J Cancer Res Ther. 2022 Dec;18(Supplement):S495-S497. doi: 10.4103/jcrt.JCRT_1018_20. J Cancer Res Ther. 2022. PMID: 36511014 Free article.